HomeCompareLTHHF vs ABBV

LTHHF vs ABBV: Dividend Comparison 2026

LTHHF yields 624.02% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LTHHF wins by $354935.28M in total portfolio value
10 years
LTHHF
LTHHF
● Live price
624.02%
Share price
$0.32
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$354935.39M
Annual income
$269,864,408,044.77
Full LTHHF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — LTHHF vs ABBV

📍 LTHHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLTHHFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LTHHF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LTHHF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LTHHF
Annual income on $10K today (after 15% tax)
$53,042.12/yr
After 10yr DRIP, annual income (after tax)
$229,384,746,838.05/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, LTHHF beats the other by $229,384,725,782.05/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LTHHF + ABBV for your $10,000?

LTHHF: 50%ABBV: 50%
100% ABBV50/50100% LTHHF
Portfolio after 10yr
$177467.74M
Annual income
$134,932,216,408.26/yr
Blended yield
76.03%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

LTHHF
No analyst data
Altman Z
256.2
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LTHHF buys
0
ABBV buys
0
No recent congressional trades found for LTHHF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLTHHFABBV
Forward yield624.02%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$354935.39M$102.3K
Annual income after 10y$269,864,408,044.77$24,771.77
Total dividends collected$347891.86M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: LTHHF vs ABBV ($10,000, DRIP)

YearLTHHF PortfolioLTHHF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$73,102$62,402.50$11,550$430.00+$61.6KLTHHF
2$504,554$426,334.41$13,472$627.96+$491.1KLTHHF
3$3,289,933$2,750,059.77$15,906$926.08+$3.27MLTHHF
4$20,278,824$16,758,596.12$19,071$1,382.55+$20.26MLTHHF
5$118,238,858$96,540,516.53$23,302$2,095.81+$118.22MLTHHF
6$652,585,293$526,069,714.93$29,150$3,237.93+$652.56MLTHHF
7$3,411,808,451$2,713,542,187.49$37,536$5,121.41+$3411.77MLTHHF
8$16,909,311,064$13,258,676,021.19$50,079$8,338.38+$16909.26MLTHHF
9$79,505,586,809$61,412,623,970.09$69,753$14,065.80+$79505.52MLTHHF
10$354,935,385,930$269,864,408,044.77$102,337$24,771.77+$354935.28MLTHHF

LTHHF vs ABBV: Complete Analysis 2026

LTHHFStock

Lithium Power International Limited, a lithium company, engages in the identification, acquisition, exploration, and development of lithium assets in Chile and Australia. The company holds 51.55% interest in the Maricunga lithium brine project covering an area of approximately 1,125 hectares located in the Atacama Region, Chile. It also holds 100% interests in the Tabba Tabba property and Pilgangoora lithium tenement located in North West Western Australia; and the Greenbushes project in the South West Western Australia. Lithium Power International Limited was incorporated in 2015 and is based in Sydney, Australia.

Full LTHHF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this LTHHF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LTHHF vs SCHDLTHHF vs JEPILTHHF vs OLTHHF vs KOLTHHF vs MAINLTHHF vs JNJLTHHF vs MRKLTHHF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.